About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Roser Ferrer Costa
IP: Desenvolupament de models animals per l'avaluació ràpida i eficient de tractaments nanotecnològics
IP: Joan López Hellin
IP: Clara Carnicer Cáceres
IP: - Collaborators: - Funding agency: EUROPEAN COMMISSION Funding: 251971.2 Reference: SPM40_F.ANDRADE_MSCA-DN2023 Duration: 01/11/2024 - 31/10/2028
IP: Simon Schwartz Navarro Collaborators: Roser Ferrer Costa, Concepció Jacobs Cachá Funding agency: EUROPEAN COMMISSION Funding: 288262.5 Reference: COMFORT- HE--JU-IHI-2023-04 Duration: 01/11/2024 - 30/04/2028
IP: M Mar Mañu Pereira Collaborators: Augusto Cesar Sao Aviles, Patricia González Ruiz, Claire Diot, Miguel Chillon Rodriguez, Simon Schwartz Navarro, Sara Isabel Reidel Funding agency: EUROPEAN COMMISSION Funding: 1252083.33 Reference: ERDERA/EC/HLTH-2023-DISEASE-07-01/2023/MAÑU Duration: 01/09/2024 - 31/08/2031
IP: - Collaborators: Roser Ferrer Costa, Diana Fernandes de Rafael Funding agency: Asociación Española Contra el Cáncer Funding: 10000 Reference: SNRGS247164DASI Duration: 01/06/2024 - 31/05/2026
PhD student: Noelia Díaz Troyano Director/s: Roser Ferrer Costa, Francisco Rodríguez Frias University: Universitat Autònoma de Barcelona Year: 2024
PhD student: Yolanda Villena Ortiz Director/s: Francisco Rodríguez Frias, Joan López Hellin University: Year: 2024
PhD student: Pablo Gabriel Medina Director/s: Roser Ferrer Costa, David Martinez Selva, David Martinez Selva University: Universitat Autònoma de Barcelona Year: 2024
PhD student: Luisa Maria Martinez Sánchez Director/s: Francisco Rodríguez Frias University: Universitat Autònoma de Barcelona Year: 2023
PhD student: Emily Marisol Toscano Guerra Director/s: Rosanna Paciucci Barzanti University: Universitat Autònoma de Barcelona Year: 2023
The study results show that the local presence of IL-1β promotes the development of myeloid cells with an immunosuppressive function.
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.
